sacubitril 24 mg valsartan 26 mg Entresto
1 INDICATIONS AND USAGE ENTRESTO is a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. ENTRESTO reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure ENTRESTO is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1)] . 1.2 Pediatric Heart Failure ENTRESTO is indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. ENTRESTO reduces NT-proBNP and is expected to improve cardiovascular outcomes.
novartis pharmaceuticals corporation
OVAL WHITE NVR LZ
NVR LZ OVAL WHITE
Related Pills
sacubitril 24 mg valsartan 26 mg Entresto
novartis pharmaceuticals corporation
sacubitril 24 mg valsartan 26 mg Entresto
novartis pharmaceuticals corporation
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
16 HOW SUPPLIED/STORAGE AND HANDLING ENTRESTO (sacubitril/valsartan) tablets are unscored, ovaloid, biconvex, and film-coated. ENTRESTO film-coated oral pellets are round, biconvex in shape, and provided in a hard capsule. All strengths are packaged in bottles as described below. ENTRESTO Tablets Sacubitril/valsartan mg/mg Color Debossment Side 1/side 2 NDC 0078-XXXX-XX Bottle of 60 Bottle of 180 24/26 violet white NVR/LZ 0659-20 0659-67 49/51 Pale yellow NVR/L1 0777-20 0777-67 97/103 Light pink NVR/L11 0696-20 0696-67 ENTRESTO SPRINKLE Sacubitril/valsartan mg/mg Color Print NDC 0078-XXXX-XX Bottle of 60 6/6 white cap and transparent body “NVR” and both parts with arrows and “04” 1231-20 15/16 yellow cap and transparent body “NVR” and both parts with arrows and “10” 1238-20 Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Protect from moisture.
More pills like OVAL NVR LZ